USA flag logo/image

An Official Website of the United States Government

Attomole-Level High-Throughput Genomics

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R44HG005279
Solicitation Year:
2011
Solicitation Topic Code:
NHGRI
Solicitation Number:
PA09-080
Small Business Information
HELICOS BIOSCIENCE CORPORATION
ONE KENDALL SQUARE CAMBRIDGE, MA 02139-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2011
Title: Attomole-Level High-Throughput Genomics
Agency: HHS
Contract: 4R44HG005279-02
Award Amount: $1,502,971.00
 

Abstract:

DESCRIPTION (provided by applicant): Tremendous advances in genomics during the past two decades hold great potential for the development of new health innovations. For this potential to be realized in the form of advances in biomedical research and novelprevention, diagnosis, treatment and disease management strategies, we must overcome one technological barrier, namely the ability to perform reliable molecular profiling analyses of low quantity cells/nucleic acid material. Current technologies are not suitable for most low-quantity nucleic applications, and require multiple nucleic acid manipulation and amplification steps that are known to introduce biases and artifacts that confound downstream analyses and reduce/eliminate quantitative power. This grantapplication proposes various strategies for picogram-level DNA and RNA samples to be profiled in an unbiased and amplification-free, high-throughput manner, and paves the way towards single cell measurements. In Phase I, we will set the groundwork for unprecedented technologies enabling attomole-level, amplification-free high- throughput genomics tools. The Phase I specific aims are: (1) Optimization of DNA tailing and sequencing surface capture steps, (2) Development of DNA fragmentation strategies suitable for low DNA quantities, (3) Specific capture and sequencing of polyA+ mRNA from total RNA, and (4) Development of single-step sequence selection and single molecule sequencing technology. In Phase II, we will expand our work from Phase I to develop mature procedures ready for commercialization. The Phase II specific aims are: (1) High- throughput sequencing of limiting DNA samples, (2) Sequencing minute polyA+ RNA quantities using direct RNA sequencing, (3) Optimization of tailing and surface capture steps for direct RNA sequencing, (4) cDNA- based low-quantity RNA sequencing on surface, and (5) Development of a sequencing strategy for damaged and limited quantity nucleic acid samples. These advancements will enable various long desired and needed studies, open new research frontiers and provide a comprehensive understanding of the biological mechanisms underlying disease states, such as cancer, heart disease, diabetes, and others, ultimately leading to revolutionary new ways to diagnose, treat and preventhuman disease. PUBLIC HEALTH RELEVANCE: The sequencing of the first human genome was an unprecedented scientific achievement derived from 13 years of effort by an international coalition of scientists and some 3 billion in funds. The availabilityof a complete human genome sequence has facilitated research by providing a framework for the genome, now being used for further investigation into the biological mechanisms underlying human disease. Technological advancements now enable sequencing of genomes at a fraction of the time and cost, and the widespread application of high-throughput sequencing technologies has transformed the biomedical research field. However, several fundamental technical shortcomings still remain. Among these limitations, arguably the most critical one is the requirement for high-quantities of valuable input material, namely DNA/RNA. Progress in many research areas, such as, but not limited to, stem cell biology, microbiology, cancer, paleoarcheology, forensics, and clinical diagnostics, is severely impeded by our inability to perform comprehensive and reliable molecular profiling analyses on low-quantity cell and nucleic acid samples. If we are to successfully translate this research knowledge of genome biology to better diagnosing and treating human disease, we must reliably use and analyze minute quantities of nucleic acid derived from patient specimens. This grant application proposes various strategies for picogram-level DNA and RNA samples to be profiled in an unbiased andamplification-free, high-throughput manner, and paves the way towards single cell measurements. These advancements will enable various long desired and needed studies, open new research frontiers and provide a comprehensive understanding of the biologicalmechanisms underlying disease states, such as cancer, heart disease, diabetes, and others, ultimately leading to revolutionary new ways to diagnose, treat and prevent human disease.

Principal Investigator:

Patrice M. Milos
617-264-1897
pmilos@helicosbio.com

Business Contact:

Patrice M. Milos
617-264-1897
pmilos@helicosbio.com
Small Business Information at Submission:

HELICOS BIOSCIENCE CORPORATION
ONE KENDALL SQUARE CAMBRIDGE, MA 02139-

EIN/Tax ID: 105058736
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No